Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Innovations (Phila) ; 19(2): 156-160, 2024.
Article in English | MEDLINE | ID: mdl-38462836

ABSTRACT

OBJECTIVE: Here we report our preclinical, proof-of-concept testing to assess the ability of a novel device to correct mitral regurgitation. The Milwaukee Heart device aims to enable any cardiac surgeon to perform high-quality mitral valve repair using a standard annuloplasty ring with a crosshatch of microporous, monofilament suture. METHODS: Hemodynamic, echocardiographic, and videographic data were collected at baseline, following induction of mitral regurgitation, and after repair using porcine hearts in an ex vivo biosimulator model. A commercially available cardiac prosthesis assessment platform was then used to assess the hydrodynamic characteristics of the study device. RESULTS: Porcine biosimulator pressure and flow metrics exhibited successful correction of mitral regurgitation following device implantation with similar values to baseline. Hydrodynamic results yielded pressure gradients and an effective orifice area comparable to currently approved prostheses. CONCLUSIONS: The study device effectively reduced mitral valve regurgitation and improved hemodynamics in our preclinical model with similar biophysical metrics to currently approved devices. Future in vivo trials are needed to evaluate the efficacy, biocompatibility, and freedom from the most likely adverse events, such as device thrombosis, embolic events, and hemolysis.


Subject(s)
Heart Valve Prosthesis , Hemodynamics , Mitral Valve Annuloplasty , Mitral Valve Insufficiency , Proof of Concept Study , Animals , Mitral Valve Annuloplasty/methods , Mitral Valve Annuloplasty/instrumentation , Swine , Mitral Valve Insufficiency/surgery , Hemodynamics/physiology , Prosthesis Design , Mitral Valve/surgery , Heart Valve Prosthesis Implantation/methods , Heart Valve Prosthesis Implantation/instrumentation , Echocardiography , Disease Models, Animal
2.
Artif Organs ; 48(6): 675-682, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38321771

ABSTRACT

INTRODUCTION: For the Veterans Health Administration (VHA) to continue to perform complex cardiothoracic surgery, there must be an established pathway for providing urgent/emergent extracorporeal life support (ECLS). Partnership with a nearby tertiary care center with such expertise may be the most resource-efficient way to provide ECLS services to patients in post-cardiotomy cardiogenic shock or respiratory failure. The goal of this project was to assess the efficiency, safety, and outcomes of surgical patients who required transfer for perioperative ECLS from a single stand-alone Veterans Affairs Medical Center (VAMC) to a separate ECLS center. METHODS: Cohort consisted of all cardiothoracic surgery patients who experienced cardiogenic shock or refractory respiratory failure at the local VAMC requiring urgent or emergent institution of ECLS between 2019 and 2022. The primary outcomes are the safety and timeliness of transport. RESULTS: Mean time from the initial shock call to arrival at the ECLS center was 2.8 h. There were no complications during transfer. Six patients (86%) survived to decannulation. CONCLUSION: These results suggest that complex cardiothoracic surgery can be performed within the VHA system and when there is an indication for ECLS, those services can be safely and effectively provided at an affiliated, properly equipped center.


Subject(s)
Extracorporeal Membrane Oxygenation , Hospitals, Veterans , Shock, Cardiogenic , United States Department of Veterans Affairs , Humans , Extracorporeal Membrane Oxygenation/methods , United States , Shock, Cardiogenic/therapy , Male , Middle Aged , Aged , Female , Respiratory Insufficiency/therapy , Cardiac Surgical Procedures/methods , Retrospective Studies , Patient Transfer
4.
Clin Case Rep ; 11(7): e7695, 2023 Jul.
Article in English | MEDLINE | ID: mdl-37465241

ABSTRACT

Postcardiotomy RV dysfunction is an under-recognized cause of acute kidney injury (AKI). Insertion of a percutaneous right ventricular assist device (RVAD) reduces central venous hypertension and congestive nephropathy by augmenting cardiac output. In selected patients, percutaneous RVAD insertion may improve renal function and obviate the need for long-term dialysis.

6.
J Thorac Cardiovasc Surg ; 166(6): e510-e511, 2023 12.
Article in English | MEDLINE | ID: mdl-36732147

Subject(s)
Heart , Holidays , Humans
7.
J Card Surg ; 37(12): 5135-5143, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36403269

ABSTRACT

OBJECTIVES: Healthcare delivery is heterogenous; the reasons for this are numerous and complex. Patient-specific factors including geography, income, insurance status, age, and gender have been shown to bias surgical outcomes. Utilizing a prospectively collected all-payer database, we aim to evaluate the influence of socioeconomic factors on mortality and length of stay (LOS) after common cardiac surgical procedures. METHODS: We utilized the National Inpatient Sample, Healthcare Cost and Utilization Project, Agency for Healthcare Research and Quality for the year 2019. We included patients undergoing coronary artery bypass grafting (CABG), aortic valve replacement (AVR), transcatheter aortic valve replacement (TAVR), and combined AVR/CABG using the 10th revision of the International Classification of Diseases procedure codes. AVR and CABG were combined into a separate cohort as this was felt to represent a different pathology than isolated valvular or coronary arterial disease. Baseline demographics were summarized. Multivariable regression was performed within each procedure group to model the odds of in-hospital mortality and hospital LOS with age, sex, insurance, zip-code median household income, and location as predictors. RESULTS: Baseline patient characteristics including gender, income, geography, and payer status were similar between CABG, AVR, and AVR/CABG. TAVR patients had a higher proportion of female sex and Medicare as the primary payer, with an overall greater age. Multivariable Cox proportional hazards regression found that higher income was strongly associated with decreased LOS following AVR and CABG, and moderately associated in TAVR and AVR/CABG. Private insurance was associated with a decreased LOS in patients undergoing CABG, AVR, TAVR, and AVR/CABG. Female sex and increased age were associated with increased odds of mortality in TAVR, CABG, and AVR/CABG. Private insurance was associated with a decreased odds of mortality in patients undergoing AVR. CONCLUSIONS: These findings reveal significant disparities in patient outcomes after routine cardiac operations that are associated with socioeconomic status. Patients who did not have private insurance or had lower incomes were found to be at risk for increased LOS. Women were at a higher risk of mortality for several operations, a finding which has been previously described elsewhere. Private insurance conveyed a decreased odds of mortality in patients undergoing AVR. This data set serves to highlight differences in healthcare outcomes based on a variety of socioeconomic, geographic, and other inherent factors. Additional research is needed to identify the mechanisms behind these disparities with the goal of providing equitable care to all patients.


Subject(s)
Aortic Valve Stenosis , Heart Valve Prosthesis Implantation , Transcatheter Aortic Valve Replacement , Humans , Female , Aged , United States/epidemiology , Aortic Valve Stenosis/surgery , Risk Factors , Treatment Outcome , Medicare , Aortic Valve/surgery , Socioeconomic Factors
8.
Thorac Surg Clin ; 31(2): 177-188, 2021 May.
Article in English | MEDLINE | ID: mdl-33926671

ABSTRACT

Lung volume reduction surgery (LVRS) patient selection guidelines are based on the National Emphysema Treatment Trial. Because of increased mortality and poor improvement in functional outcomes, patients with non-upper lobe emphysema and low baseline exercise capacity are determined as poor candidates for LVRS. In well-selected patients with heterogeneous emphysema, LVRS has a durable long-term outcome at up to 5-years of follow-up. Five-year survival rates in patients range between 63% and 78%. LVRS seems a durable alternative for end-stage heterogeneous emphysema in patients not eligible for lung transplantation. Future studies will help identify eligible patients with homogeneous emphysema for LVRS.


Subject(s)
Life Expectancy , Lung/surgery , Pneumonectomy/adverse effects , Pneumonectomy/methods , Pulmonary Emphysema/surgery , Aged , Clinical Trials as Topic , Female , Guidelines as Topic , Humans , Kaplan-Meier Estimate , Lung Transplantation , Male , Middle Aged , Patient Selection , Pulmonary Emphysema/mortality , Pulmonary Emphysema/physiopathology , Survival Rate , Treatment Outcome
10.
Ann Thorac Surg ; 108(3): 866-872, 2019 09.
Article in English | MEDLINE | ID: mdl-31055037

ABSTRACT

BACKGROUND: Lung volume reduction surgery (LVRS) is the definitive treatment for patients with severe emphysema. There is still a need for long-term data concerning the outcomes of this procedure. This study presents long-term longitudinal data on LVRS including correlation of quality of life (QOL) with pulmonary function testing metrics and includes additional analysis of patients with heterogeneous and homogeneous emphysema. METHODS: Retrospective analysis of data collected from patients undergoing LVRS over a 9-year period at a single center was performed (N = 93). Pulmonary function and 6-minute walk tests as well as QOL questionnaires were administered before and 1 year after surgery. Descriptive statistics were reported for clinical outcomes and QOL indices. Wilcoxon signed-rank tests were used to examine changes from baseline to end of 1-year follow-up. Spearman correlation coefficients were used to evaluate relationships between clinical and QOL outcomes. RESULTS: At 1-year post surgery, mean forced vital capacity (46%, P ≤ .0001), forced expiratory volume (43%, P ≤ .0001), diffusing capacity of the lungs for carbon monoxide (16%, P ≤ .0001), and 6-minute walk distance (20%, P ≤ .0001) were increased from baseline, while residual volume decreased (23%, P ≤ .0001). There was a positive correlation between changes in QOL and forced expiratory volume, forced vital capacity, and, 6-minute walk distance. Patients having heterogeneous disease had greater improvements in forced expiratory volume, forced vital capacity, residual volume, and diffusing capacity of the lungs for carbon monoxide, and greater QOL compared with patients with homogeneous disease. CONCLUSIONS: LVRS continues to be a valuable treatment option for patients with advanced emphysema with reproducible improvements in clinical and QOL metrics. Careful patient selection and optimization prior to surgery are crucial to successful outcomes.


Subject(s)
Hospital Mortality , Pneumonectomy/methods , Pneumonectomy/psychology , Pulmonary Emphysema/surgery , Quality of Life , Academic Medical Centers , Aged , Female , Follow-Up Studies , Forced Expiratory Volume , Humans , Illinois , Length of Stay , Longitudinal Studies , Male , Middle Aged , Patient Selection , Pneumonectomy/mortality , Pulmonary Emphysema/diagnosis , Pulmonary Emphysema/mortality , Pulmonary Emphysema/psychology , Respiratory Function Tests , Retrospective Studies , Risk Assessment , Statistics, Nonparametric , Survival Analysis , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...